Core Viewpoint - The article emphasizes the importance of awareness and preventive measures against viral hepatitis, highlighting that it is preventable and treatable, and calls for collective action to eliminate its harm [1][2]. Group 1: Understanding Hepatitis - The liver is referred to as the body's largest "chemical factory," responsible for synthesis, metabolism, detoxification, and defense [1]. - Hepatitis is categorized into viral and non-viral types, with viral hepatitis being infectious and having specific transmission routes, including hepatitis A, B, C, D, and E [1]. - Non-viral hepatitis includes alcoholic hepatitis, fatty liver, autoimmune liver disease, and genetic metabolic diseases [1]. Group 2: Prevention and Treatment - Vaccination, blocking transmission routes, and adopting healthy lifestyle habits are effective preventive measures against viral hepatitis [2]. - Vaccines can effectively prevent infections of hepatitis A, B, and E, while hepatitis C can often be treated and cleared with short-term antiviral therapy [2]. - Early detection is crucial as many viral hepatitis infections lack specific symptoms in the early stages; recommended screening includes liver function tests and hepatitis virus quantification [2].

Core Viewpoint - The vaccine industry is expected to see a recovery in sales growth trends for key vaccine varieties in 2025, driven by a low base effect, which will improve company performance [1] Industry Summary - In Q1 2025, the overall number of vaccine batch approvals was 697, representing a year-on-year decline of 14% [1] - Significant year-on-year growth was observed in flu vaccines, DTP vaccines, and hepatitis vaccines, while polio vaccines, shingles vaccines, rotavirus vaccines, and HPV vaccines experienced notable declines [1] - The development of therapeutic vaccines for cancer is emerging as a hot area for vaccine indication expansion, with domestic research still in its early stages [1] - The competitive landscape for traditional key vaccine pipelines is intensifying, with many domestic companies entering the market [1] Company Summary - It is anticipated that key vaccine varieties will recover in sales growth in 2025, which will positively impact company performance [1] - Continuous advancement in innovative vaccine pipelines is expected to provide companies with greater market opportunities and potential for international expansion in the future [1]